logo
    Mantle cell lymphoma treatment: plus ça change…
    The Lancet (2016)
    Peter Martin
    3
    Citation
    13
    Reference
    10
    Related Paper
    Citation Trend
    Keywords:
    Autologous stem-cell transplantation
    Topics:
    Lymphoma Diagnosis and Treatment
    Viral-associated cancers and disorders
    CNS Lymphoma Diagnosis and Treatment
    Mantle cell lymphoma as a component of composite lymphoma: clinicopathologic parameters and biologic implications
    Human Pathology (2012)
    Thomas PapathomasIoannis VenizelosCherie H. DunphyJonathan W. SaidMichael Wang
    Citations (21)
    Autologous Stem Cell Transplantation In Mantle Cell Lymphoma: The Experience of the French SFGM-TC Group
    Blood (2010)
    Cyrille TouzeauRichard DelarueChristophe LeuxMurielle RousselKrimo Bouabdallah
    Autologous stem-cell transplantation
    Citations (2)
    Mantle cell lymphoma and diffuse large B‐cell lymphoma of the testis: a unique case of composite non‐Hodgkin lymphoma
    European Journal Of Haematology (2014)
    Swati AndhavarapuJennifer A. CrozierLiuyan JiangTaimur Sher
    Abstract Primary testicular non‐Hodgkin lymphoma ( NHL ) is a rare entity with the most common histologic subtype consisting of diffuse large B‐cell lymphoma ( DLBCL ). Patients with primary testicular lymphoma ( PTL ) have a poor prognosis and a higher propensity for relapse. Also rare are composite lymphomas ( CL ) defined as two or more morphologically and phenotypically distinct lymphomas coexisting in a single organ or tissue. Here we present the first reported case of primary testicular composite lymphoma consisting of DLBCL and mantle cell lymphoma ( MCL ).
    Citations (8)
    Long-Term Clinical and Molecular Remissions in Patients with Mantle Cell Lymphoma (MCL) Following High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)
    Blood (2019)
    Bernd MetznerJochen CasperKoehne Claus-HenningAndrea RenzelmannThomas Mueller
    Autologous stem-cell transplantation
    Citations (0)
    Indolent lymphomas and mantle cell lymphoma: New developments as of ASH 2010
    memo - Magazine of European Medical Oncology (2011)
    Johannes Drach
    Autologous stem-cell transplantation
    Bendamustine
    Follicular lymphoma
    Ibritumomab tiuxetan
    Hematology
    Regimen
    Citations (1)
    Toward New Treatments for Mantle-Cell Lymphoma?
    New England Journal of Medicine (2013)
    Emanuele ZuccaFrancesco Bertoni
    Mantle-cell lymphoma is a lymphoma subtype characterized by the overexpression of cyclin D1 and the dysregulation of the cell cycle. Many secondary genetic events contribute to growth in mantle-cell lymphoma, including the loss of DNA damage-response capacity, the activation of cell-survival pathways, and the inhibition of apoptosis.1,2 The prognosis in mantle-cell lymphoma is the worst among B-cell lymphomas. Remissions achieved with conventional chemotherapy are often short-lived, and very intensive regimens, including stem-cell transplantation, seem necessary to improve the outcome, but they are feasible in only a limited number of patients.3 Ibrutinib (PCI-32765) is an orally active irreversible inhibitor of . . .
    Citations (20)
    High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma.
    PubMed (2005)
    Stéphane VigourouxFanny GaillardPhilippe MoreauJean‐Luc HarousseauNöel Milpied
    We retrospectively investigated the outcome of 30 newly diagnosed patients with mantle cell lymphoma treated with high-dose therapy and autologous stem cell transplantation in first response. With a median follow-up of 55 months, the 5-year overall-survival is 62%, the 5-year progression-free-survival is 40% and no secondary malignancy has occurred.
    Autologous stem-cell transplantation
    Citations (32)
    Mantle cell lymphoma: established therapeutic options and future directions
    Annals of Hematology (2004)
    Georg LenzMartin DreylingWolfgang Hiddemann
    Hematology
    Autologous stem-cell transplantation
    Citations (78)
    Mantle cell lymphoma treatment: plus ça change…
    The Lancet (2016)
    Peter Martin
    Autologous stem-cell transplantation
    Citations (3)
    Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma.
    HAL (Le Centre pour la Communication Scientifique Directe) (2006)
    Sophie de GuibertArnaud JaccardMaryse BernardPascal TurlureDominique Bordessoule
    We report on a series of 24 patients with newly diagnosed mantle cell lymphoma treated with four to six courses of DHAP-rituximab followed by autologous stem cell transplantation for patients <65 years. Three-year overall survival (OS) and event free survival (EFS) rates were 69% and 65% respectively, for the 24 patients. In intent-to-treat analysis, 3-year OS and EFS were 75% and 76% for the 17 patients < 65 years old. This treatment is quite feasible and compares favourably with other regimens.
    Autologous stem-cell transplantation
    DHAP
    First line therapy
    Citations (49)